Prednisolone prevents decreases in trabecular bone mass and strength by reducing bone resorption and bone formation defect in adjuvant-induced arthritic rats.
We examined the effects of prednisolone (PSL) administration in normal female Sprague Dawley rats and adjuvant-induced arthritic rats at the age of 6 weeks. Rats were intramuscularly injected with PSL twice a week at doses of 0 (control), 10, 30, 90, or 270 mg/kg body weight (b.w.). In the normal rats, serum osteocalcin level at 14 days and serum carboxyterminal pyridinoline cross-linked telopeptide of type 1 collagen (1CTP) level at 28 days in the 270 mg/kg dose group was lower than the respective value in control animals. The BMC and the trabecular bone formation rate (BFR/BS) of the lumbar body (L-4) in the 270 mg/kg dose group at 14 and 28 days were significantly lower than the values in the control rats. In the arthritic rats, however, serum osteocalcin levels in the PSL-treated groups did not differ compared with arthritic controls. The serum 1CTP levels in all of the PSL-treated groups were significantly reduced at 28 days. The age-dependent increases in the L4 BMC, BMD, and L-3 ultimate compressive load values were maintained. The BFR/BS values in the 90 mg/kg and 270 mg/kg dose groups were significantly higher than those in the arthritic control rats. The trabecular osteoclast number and surface values in all of the PSL-treated groups were significantly lower than the values in arthritic controls. These data demonstrate that PSL administration prevented reduction in bone mass and strength of the lumbar trabecular bone in adjuvant-induced arthritic rats by reducing the increase in bone resorption and the decrease in bone formation at both the local and systemic levels.
Okazaki
Y
Y
Department of Orthopedic Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tsurukami
H
H
Nishida
S
S
Okimoto
N
N
Aota
S
S
Takeda
S
S
Nakamura
T
T
D000818:Animals; D001169:Arthritis, Experimental / Q000150:complications*; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D001862:Bone Resorption / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D004487:Edema / Q000188:drug therapy; D005260:Female; D005620:Freund's Adjuvant; D005938:Glucocorticoids / Q000494:pharmacology*; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D015675:Osteocalcin / Q000097:blood; D010010:Osteoclasts / Q000187:drug effects / Q000502:physiology; D010455:Peptides / Q000097:blood; D011239:Prednisolone / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016474:Weight-Bearing / Q000502:physiology
D024042:Collagen Type I; D005938:Glucocorticoids; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D003094:Collagen; D005620:Freund's Adjuvant; D011239:Prednisolone